compounds that can be released from packaging materials under aggressive laboratory conditions, whereas leachables are substances that migrate into the drug product under normal storage conditions. GMP-compliant controls for E&L require a robust understanding of both concepts and their potential impact on different dosage forms.

Step 1: Define Dosage Form and Packaging Material Combinations

• Identify the dosage form type: solid oral (tablets, capsules), parenteral (injectables, sterile solutions), topical (creams, ointments), inhalation (MDIs, DPIs), or combination products (device-drug).
• Catalogue packaging components: primary container (blister, vial, bottle), closures (caps, seals), secondary packaging, and delivery devices where applicable.
• Map material types: plastics (polyethylene, polypropylene, PVC), rubber (elastomers), glass, metals, coatings, and printing inks.

Establishing this matrix is foundational to GMP-based E&L risk management. The physical and chemical nature of each component governs the profile of potential extractables and subsequent leachables in the final product.

Step 2: Review Regulatory Expectations and Guidance

Consult relevant regulatory guidance to align your E&L control strategy with agency expectations. For example, the FDA’s guidance on container closure systems, the European Medicines Agency’s Annex 1 (sterile products), PIC/S PE 009, and ICH Q3E (Impurities: Guideline for Residual Solvents) provide frameworks to ensure risk-based control. These collectively emphasize the importance of packaging qualification during product development under GMP.

FDA Container Closure System Guidance offers detailed directions on acceptable materials and testing methodologies, including extractables and leachables assessments.

2. Risk Assessment and Planning for GMP Controls Across Dosage Forms

Implementing GMP controls for dosage form and packaging interaction begins with a thorough risk assessment focused on extractables and leachables. This aligns with ICH Q9 principles for quality risk management and Annex 15 requirements for qualification.

Step 3: Perform Initial Risk Assessment

• Evaluate the chemical compatibility between the drug formulation and packaging materials.
• Consider dosage form vulnerability to leachables—for example, parenteral products demand the highest risk scrutiny due to direct injection into patients.
• Account for storage conditions, shelf life, and intended routes of administration.
• Identify any prior knowledge or data on extractables profiles from similar materials or products.

Step 4: Develop a Risk-Based Testing Strategy

Design your E&L testing program to cover:

• Extractables Testing: Conduct exaggerated condition testing (e.g., elevated temperature, solvents) of packaging components to define all possible leachable candidates.
• Leachables Testing: Analyze actual drug product stored under defined GMP conditions to measure chemicals migrating during shelf life.

Test methods should include appropriate chromatography, mass spectrometry, and spectroscopic techniques designed and validated according to GMP for pharmaceutical analytical methods.

For solid oral products such as tablets and capsules, tablet manufacturing and capsule GMP requirements emphasize that packaging must prevent moisture ingress and maintain stability. Packaging extractables testing should focus on moisture barrier films and inks. In parenteral and sterile injectables, sterilizability and extractables from rubber stoppers and glass vials are critical control points.

3. Implementing GMP Controls in Packaging Selection and Manufacturing

Appropriate GMP controls during packaging selection, supplier qualification, and manufacturing execution ensure control of E&L risks.

Step 5: Supplier and Material Qualification under GMP

• Assess suppliers for compliance with GMP and quality systems relevant to packaging materials.
• Require complete documentation of material composition, extractables data, and safety profiles.
• Verify consistency of batch-to-batch material quality with sampling and testing plans.

Implement documented supplier audits and quality agreements to assure compliance with GMP and regulatory requirements.

Step 6: Packaging Material Testing and GMP Release Controls

• Set acceptance criteria for extractables based on toxicological evaluation and comparison to permitted daily exposure (PDE) limits.
• Institute in-process controls during packaging operations to monitor environmental conditions, material handling, and container closure integrity.
• Document all testing and controls within GMP batch records, analytical reports, and validation protocols.

It is vital to recognize that packaging controls differ by dosage form. For example, inhalation products require stringent control of propellants and polymers to minimize extractables that could affect aerosol performance or patient safety. Combination products require synergy between GMP for devices and pharmaceuticals, adding layers of complexity.

4. Stability, Monitoring, and Ongoing GMP Control of Extractables and Leachables

Once packaging and dosage form compatibility is established and qualified, ongoing GMP monitoring is critical through the product lifecycle.

Step 7: Incorporate E&L Testing Within Stability Studies

Under GMP supervision, leachables testing should be integrated into stability protocols according to established product storage conditions. This monitoring provides real-world data on chemical migration trends and confirms previous risk assessments.

EMA Guidelines on Extractables and Leachables outline best practices for stability-related leachables evaluation within the GMP framework.

Step 8: Implement Ongoing GMP Trending and Investigation

• Establish key performance indicators (KPIs) relating to packaging quality and E&L findings.
• Investigate any deviations or out-of-specification results through formal GMP deviation management and CAPA processes.
• Periodically review supplier performance, material requalification, and risk assessments in line with GMP lifecycle management.

Regular communication with regulatory bodies during product lifecycle changes ensures continued compliance, particularly for sterile injectables where packaging integrity and E&L controls are critically inspected during GMP audits.

5. Regulatory Inspection Readiness and Documentation Practices for E&L GMP Controls

Proper documentation and inspection preparation are paramount to demonstrate GMP compliance relating to dosage form and packaging E&L controls.

Step 9: Prepare Comprehensive Documentation

• Master validation plans and reports covering extractables and leachables testing must be available for review.
• Risk assessments, supplier qualifications, and material certifications should be organized and easily accessible.
• Analytical method validation, batch testing results, and stability data must be maintained in line with PIC/S GMP expectations.

Step 10: Conduct Internal GMP Audits Focused on Packaging Interactions

Internal audits should include verification of packaging material controls, E&L testing adherence, and packaging defect management. Observing cleanroom gowning and handling practices during packaging operations for sterile and parenteral products is also critical.

Employing a risk-based audit approach ensures that GMP controls for combination products, inhalation devices, and high-risk solids are scrutinized with dedicated focus.

PIC/S Inspection Guidance on Extractables and Leachables provides pragmatic advice on inspector expectations during GMP audits and dossier reviews.

Summary and Key Takeaways for GMP Practitioners

Managing extractables and leachables in dosage form and packaging interactions is an integral part of pharmaceutical GMP. Through a structured, stepwise approach—from initial product and packaging definition, regulatory alignment, risk-based testing, supplier qualification, to ongoing GMP monitoring and documentation—pharmaceutical manufacturers can ensure patient safety and regulatory compliance.

• Understand your dosage form and packaging materials in detail.
• Perform thorough risk assessments and design GMP-compliant testing strategies.
• Qualify and control suppliers and packaging materials rigorously under GMP.
• Integrate extractables and leachables monitoring into stability and routine batch testing.
• Maintain comprehensive GMP documentation and prepare for thorough inspections.

Adhering to these GMP steps will enable pharma professionals operating in the US, UK, and EU to maintain high standards of product quality and ensure patient safety by minimizing risks associated with drug product-packaging interactions.